Molecular Partners Ag (MOLN) Free Cash Flow (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Free Cash Flow of -$18188.4 for Q1 2026, up 1.68% year-on-year from -$17888.1 in Q1 2025, and up 99.97% on a QoQ basis from -$65.0 million in Q4 2025.
Molecular Partners Ag (MOLN) Free Cash Flow (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Free Cash Flow for 7 consecutive years, with -$18188.4 the latest figure, recorded in Q1 2026.
- Quarterly Free Cash Flow rose 1.68% year-over-year to -$18188.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.8 million (up 4.63% YoY) and the FY2025 annual result came in at -$65.0 million, up 4.99% from the prior year.
- Free Cash Flow advanced to -$18188.4 in Q1 2026 per MOLN's latest filing, from -$65.0 million in the prior quarter.
- Over the last five years, Free Cash Flow for MOLN reached as high as $157.0 million in Q2 2022 and fell as low as -$156.6 million in Q3 2022.
- A 5-year average of -$4.4 million and a median of -$18499.0 in 2025 frame the typical range for Free Cash Flow.
- The largest YoY upside for Free Cash Flow was 633.09% in 2022 against a maximum downside of 375.79% in 2022.
- Year by year, Free Cash Flow stood at $121.7 million in 2022, then plunged by 155.15% to -$67.1 million in 2023, then fell by 1.89% to -$68.4 million in 2024, then rose by 4.99% to -$65.0 million in 2025, then soared by 99.97% to -$18188.4 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$18188.4, -$65.0 million, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -18,188.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,188.38 |
| Mar 31, 2026 | -18,188.38 |
| Dec 31, 2025 | -64.98 Mn |
| Dec 31, 2025 | -64.98 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Jun 30, 2025 | -35.78 Mn |
| Jun 30, 2025 | -35.78 Mn |
| Mar 31, 2025 | -18,498.95 |
| Mar 31, 2025 | -18,498.95 |
| Dec 31, 2024 | -68.39 Mn |
| Dec 31, 2024 | -68.39 Mn |
| Sep 30, 2024 | 37.41 Mn |
| Sep 30, 2024 | 37.41 Mn |
| Jun 30, 2024 | -35.87 Mn |
| Jun 30, 2024 | -35.87 Mn |
| Mar 31, 2024 | -19,392.96 |
| Mar 31, 2024 | -19,392.96 |
| Dec 31, 2023 | -67.12 Mn |
| Dec 31, 2023 | -67.12 Mn |